Association of Fenofibrate Add-on Therapy with Postoperative Diabetic Retinal Outcomes After Cataract Surgery in Patients with Type 2 Diabetes Mellitus
In brief
Fenofibrate plus statins linked to 32% fewer macular edema events after cataract surgery
In a matched retrospective study of adults with type 2 diabetes, those taking fenofibrate plus a statin had a 32% lower five-year hazard of a composite of diabetic macular edema diagnosis or injection than those taking a statin alone. Findings for proliferative retinopathy were inconclusive, and prospective studies are needed to confirm whether the association reflects a treatment benefit.
- Journal
- Retina (Philadelphia, Pa.) (Q1)
- Published
- 9 November 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Yan-Jie Su, Hsin-Ho Chang, Min-Huei Hsu, Sheng-Chu Chi
- PMID
- 43002646
- DOI
- 10.1097/IAE.0000000000005050
Why clinicians should know about it
- Picked for Ophthalmology (paper of the day, 12 November 2026): Assesses diabetic retinal outcomes after cataract surgery
Abstract
PURPOSE: To examine whether preoperative fenofibrate-plus-statin exposure was associated with postoperative diabetic macular edema (DME)-related and proliferative diabetic retinopathy (PDR)-related composites compared with statin exposure alone. METHODS: This retrospective cohort study used the TriNetX Global Collaborative Network. Adults with type 2 diabetes undergoing cataract surgery who received fenofibrate plus statin therapy were matched 1:1 with those receiving statin therapy alone. The co-primary outcomes were a DME-related composite, defined by a DME diagnosis or intravitreal injection, and a PDR-related composite comprising PDR, panretinal photocoagulation, or vitreous hemorrhage. Cox models estimated hazard ratios (HRs) over cumulative 1- to 5-year horizons. Sensitivity analyses evaluated 6-month outcomes, recent preoperative fenofibrate exposure, a laboratory-complete cohort, and Nd:YAG capsulotomy. RESULTS: Matching yielded 2,521 pairs. After outcome-specific exclusions, the DME-related composite analysis included 2,292 exposed and 2,327 comparator patients. Fenofibrate-plus-statin exposure was associated with a lower hazard of the DME-related composite at every horizon, including 1 year (HR, 0.486 [95% confidence interval [CI], 0.324-0.728], P < 0.001) and 5 years (HR, 0.678 [95% CI, 0.515-0.892], P = 0.005). For the PDR-related composite, the 95% CI excluded 1.0 only at 2 years (HR, 0.605 [95% CI, 0.397-0.922], P = 0.018). Sensitivity analyses using a recent-exposure definition and a laboratory-complete cohort generally supported the DME-related composite finding, whereas Nd:YAG capsulotomy hazards were similar between groups. CONCLUSION: Preoperative fenofibrate-plus-statin exposure was associated with a lower hazard of the postoperative DME-related composite, while findings for the PDR-related composite were inconclusive. Prospective validation is needed.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.